Commercial Insight: Antidyslipidemics

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-06-08

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The next 10 years will see six statins lose patent protection, with the potential loss of over $20 billion across the seven major markets. However, their established position as first-line therapy will see the major classes maintain volume sales, although price (and hence value) will be driven down as generic competition tries to gain a share of this highly lucrative market.


Scope

  • Country specific event-driven sales forecasts for the period 2005-14 for the US, Japan, France, Germany, Italy, Spain, the UK, and globally
  • Overview of patient potential and prescribing trends in the antidyslipidemics market based on historical sales data and future key events
  • Examination of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
  • Case studies present the reasons for the success of ezetimibe, and Pfizer's strategy with atorvastatin/torcetrapib to maintain the Lipitor franchise


    • Report Highlights
    Fears of potentially fatal rhabdomyolysis with statin use have led to a significant increase in use of adjunct therapies such as fibrates and nicotinic acid derivatives. However, Datamonitor believes their use will plateau and then decline over the next 10 years as attention shifts to newer drug classes.

    Zetia and Vytorin will dominate second-line therapy in the next 10 years, with Vytorin likely to replace Zetia as second-line therapy of choice. Ezetimibe addresses two unmet needs: provision of HMG-CoA reductase inhibition at lower statin doses and access of difficult-to-reach patient populations.

    Greater focus on aspects of the lipid profile in addition to LDL, such as TG and HDL is creating an opportunity for combination therapies. Atorvastatin + torcetrapib is expected to have a major impact on the dyslipidemia market and is expected to compete with both atorvastatin and the simvastatin + ezetimibe combination, Vytorin.


    Reasons to Purchase

  • View independent, event-driven forecasts for key antidyslipidemic products and classes across the seven major markets.
  • Identify possible future strategies to maximize product potential and compete against new adjunctive therapies.
  • Redesigned report template presents executive summary in an accessible PowerPoint format allowing rapid access to the key insights.

    • Table of Contents

    Other users found this report page using the following search terms: Dyslipidemia Antidyslipidemia Antidyslipidemic AntiDyslipidemia Antidyslipidemia Antidyslipidemic Antidyslipidemic obesity cholesterol lipitor ppt market case vytorin atorvastatin antidyslipidemia date dyslipidemia patent

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.